Release Date: 19/06/14 13:57 Summary: Supplementary Target's Statement Price Sensitive: Yes Download Document 478.5KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%